On Monday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Amarin (NASDAQ:AMRN), Horizon Pharma (NASDAQ:HZNP), Green Plains (NASDAQ:GPRE), Wabash National (NYSE:WNC)
On March 16, 2015 Amarin Corporation plc (ADR) (NASDAQ:AMRN) proclaimed the presentation of findings from a new in vitro study showing that pretreatment with eicosapentaenoic acid (EPA), an omega-3 fatty acid, reduced oxidation of small dense LDL (sdLDL) and resulted in improved endothelial function when compared to other triglyceride (TG)-lowering agents, including fenofibrates, niacin and gemfibrozil. The research was presented today at a peer-reviewed poster session at the American College of Cardiology Scientific Session in San Diego, California.
Amarin Corporation plc (ADR) (NASDAQ:AMRN) decreased -2.78%, and closed at $2.45. The company holds the market capitalization of $444.10M. For the last twelve months, the stock was able to keep return on equity at 85.20%, while return on assets at -28.90%, in response to its return on investment at -42.20%. Its 20-day moving average gained 24.68%, below 50-day moving average of 69.81%, below 200-day moving average of 77.85% from the latest market price of $2.45. The mean recommendation of analysts for this stock is 2.30. (Where 1=Buy, 5=Sale).
Amarin Corporation plc (ADR) (AMRN) a biopharmaceutical corporation focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
Formerly On March 13, 2015 Horizon Pharma PLC (NASDAQ:HZNP) promulgated that Horizon Pharma Investment Limited, its fully-owned partner (the “Issuer”), closed its offering of $400 million aggregate main amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The closing comprised of the exercise in full of the initial purchasers’ option to purchase up to an additional $50 million aggregate principal amount of the notes.
Horizon Pharma PLC (NASDAQ:HZNP) declined -2.77%, and closed at $22.14. The company has the market capitalization of $2.85 billion. The beta value of the stock is 2.36. On the other hand the stock’s volatility for the week is 3.42%, and for the month is 3.94%. The stock’s price to book ratio is $4.74, however price to sale ratio is $9.33. Analyst’s mean recommendation regarding this stock is 1.60. (Where 1=Buy, 5=Sale).
Horizon Pharma PLC (HZNP) a specialty biopharmaceutical corporation, holds in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Formerly On March 9, 2015 Green Plains Inc (NASDAQ:GPRE) disclosed that its newly-formed partner, Green Plains Partners LP , has confidentially presented a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission. The registration statement is for a projected underwritten initial public offering (“IPO”) of ordinary units representing limited partner interests in the newly-formed Partnership. It is anticipated that the IPO will raise about $200-$250 million in gross proceeds; however, the date, number of ordinary units to be sold and the price range for the projected IPO have not yet been determined and are subject to a number of factors, counting market conditions.
Green Plains Inc (NASDAQ:GPRE) fell -2.75%, and closed at $26.92. The stock has the beta value of 1.21, and its volatility for the week is 5.09%, while for the month it is 5.43%. The company has the market capitalization of $1.04 billion. The company holds the book value per share of 21.23, whereas cash per share is 11.31. Price to book ratio remained 1.27, while price to sale ratio is 0.31. Analysts mean recommendation for the stock is said to be 2.30 (where 1=Buy, 5=sale).
Green Plains Inc (GPRE) produces, markets, and distributes ethanol in the United States. The corporation operates through four segments: Ethanol Production, Corn Oil Production, Agribusiness, and Marketing and Distribution.
On 23 March,2015 Wabash National Corporation (NYSE:WNC) disclosed that it has closed on a new, $192.8 million Senior Secured Term Facility with a maturity in March, 2022. The proceeds from the new facility have been used to repay in full the outstanding balance on the Corporation’s previous Senior Secured Term Facility which was planned to mature in May, 2019. The new facility was issued without any financial covenants and an interest rate reduction of 25 basis points contrast to the previous facility.
Wabash National Corporation (NYSE:WNC)’s shares picked down -2.70%, and closed at $13.69. The stock volatility for the week is 3.34%, while for the month remained 2.33%. The company holds consensus target price of $14.70.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.85 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 26.90% and Annual EPS growth for the past 5 years is considered as 17.50%.
The mean recommendation of analysts for this stock is 2.40. (Where 1=Buy, 5=Sale).
Wabash National Corporation (WNC) produces, and markets truck and tank trailers, intermodal equipment, and transportation related products in North America. Its Commercial Trailer Products segment provides dry van trailers under the DuraPlate, DuraPlateHD, DuraPlate, XD-35, and FreightPro trademarks; platform trailers under the Transcraft, Eagle, and Benson trademarks; refrigerated trailers under the ArcticLite trademark; and specialty products, such as converter dollies, big tire haulers, Roadrailer trailers, rail products, aftermarket component products, parts, and others, in addition to used trailers and laminated hard wood oak products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
